Jefferies Flips Stance on Hearing Aid Giants

Analyst Rating Changes

Jefferies has reversed its investment ratings for Europe's two largest hearing aid manufacturers, Demant and Sonova. The firm upgraded Demant's stock to “buy” from a previous “hold” rating.

In contrast, Sonova was downgraded to “underperform” from “hold”, signaling a significant shift in the analyst's outlook for the two competitors.

Rationale Behind the Shift

The decision was driven by what Jefferies describes as an unsustainable valuation gap between the two companies. The firm also cited that favorable market tailwinds that previously benefited Sonova are now beginning to fade.

This reevaluation points to changing competitive dynamics within the hearing aid sector.

New Price Target Implications

Reflecting its positive outlook, Jefferies set a new price target for Demant at DKK245, which implies a potential 32% upside from its last closing price.

Conversely, Sonova's price target was substantially cut to CHF155 from CHF215, suggesting a potential 18% downside for the stock.

Summary and Outlook

This strategic reversal by a major analyst firm underscores shifting fundamentals in the European hearing aid market. Investors will closely monitor how these revised valuations impact share prices and whether other financial institutions adjust their positions accordingly.

FAQ

Q: Why did Jefferies upgrade Demant?
A: Jefferies upgraded Demant to “buy”, citing an unsustainable valuation gap with its main competitor and a more favorable outlook.

Q: What is the new price target for Sonova?
A: Sonova's price target was reduced to CHF155, implying a potential downside of 18% from its recent price.

Source: Investing.com